Elevated IgG autoantibody production in oligoarticular juvenile idiopathic arthritis may predict a refractory course

Matthew L. Stoll, Quan Zhen Li, Jinchun Zhou, Marilynn Punaro, Nancy J. Olsen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Although oligoarticular juvenile idiopathic arthritis (oJIA) is considered to carry the best prognosis among the JIA subtypes, many children evolve to a chronic course. A few studies have identified clinical risk factors for disease extension, and recent studies have evaluated synovial fluid markers. However, the only biological marker from the serum studied to date is the anti-nuclear antibody (ANA), regarding which there is mixed data regarding prognosis. No studies have evaluated whether additional autoantibodies may affect the articular prognosis of oJIA. Methods: Microarrays containing candidate autoantigens were printed on slides, which were used to profile 36 children with oJIA and 18 controls. Unsupervised cluster analysis was used to identify distinct subgroups of JIA patients. Response to therapy after a mean interval of 4.9 months was evaluated. Results: Cluster analysis revealed two subgroups of oJIA patients, with identical clustering observed when children with onset over age six were excluded. Cluster 1 had higher levels of multiple autoantibodies compared to both cluster 2 as well as controls, including antibodies against several extracellular matrix (ECM) and nuclear antigens. Although the two patient clusters were similar with respect to clinical features and treatment decisions, children in cluster 1 were less likely to have attained remission by the follow-up visit. Conclusion: Antibodies against ECM and possibly other antigens may identify a sub-group of children with oJIA who will require more aggressive therapy to attain control of the arthritis.

Original languageEnglish (US)
Pages (from-to)736-742
Number of pages7
JournalClinical and Experimental Rheumatology
Volume29
Issue number4
StatePublished - Jul 2011

Fingerprint

Juvenile Arthritis
Autoantibodies
Immunoglobulin G
Cluster Analysis
Extracellular Matrix
Nuclear Antigens
Antibodies
Synovial Fluid
Autoantigens
Age of Onset
Arthritis
Anti-Idiotypic Antibodies
Therapeutics
Joints
Biomarkers
Antigens
Serum

Keywords

  • Antibodies
  • Juvenile idiopathic arthritis
  • Oligoarticular

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Elevated IgG autoantibody production in oligoarticular juvenile idiopathic arthritis may predict a refractory course. / Stoll, Matthew L.; Li, Quan Zhen; Zhou, Jinchun; Punaro, Marilynn; Olsen, Nancy J.

In: Clinical and Experimental Rheumatology, Vol. 29, No. 4, 07.2011, p. 736-742.

Research output: Contribution to journalArticle

Stoll, Matthew L. ; Li, Quan Zhen ; Zhou, Jinchun ; Punaro, Marilynn ; Olsen, Nancy J. / Elevated IgG autoantibody production in oligoarticular juvenile idiopathic arthritis may predict a refractory course. In: Clinical and Experimental Rheumatology. 2011 ; Vol. 29, No. 4. pp. 736-742.
@article{dc2ee744d2aa453b975f6a3e64178e71,
title = "Elevated IgG autoantibody production in oligoarticular juvenile idiopathic arthritis may predict a refractory course",
abstract = "Objective: Although oligoarticular juvenile idiopathic arthritis (oJIA) is considered to carry the best prognosis among the JIA subtypes, many children evolve to a chronic course. A few studies have identified clinical risk factors for disease extension, and recent studies have evaluated synovial fluid markers. However, the only biological marker from the serum studied to date is the anti-nuclear antibody (ANA), regarding which there is mixed data regarding prognosis. No studies have evaluated whether additional autoantibodies may affect the articular prognosis of oJIA. Methods: Microarrays containing candidate autoantigens were printed on slides, which were used to profile 36 children with oJIA and 18 controls. Unsupervised cluster analysis was used to identify distinct subgroups of JIA patients. Response to therapy after a mean interval of 4.9 months was evaluated. Results: Cluster analysis revealed two subgroups of oJIA patients, with identical clustering observed when children with onset over age six were excluded. Cluster 1 had higher levels of multiple autoantibodies compared to both cluster 2 as well as controls, including antibodies against several extracellular matrix (ECM) and nuclear antigens. Although the two patient clusters were similar with respect to clinical features and treatment decisions, children in cluster 1 were less likely to have attained remission by the follow-up visit. Conclusion: Antibodies against ECM and possibly other antigens may identify a sub-group of children with oJIA who will require more aggressive therapy to attain control of the arthritis.",
keywords = "Antibodies, Juvenile idiopathic arthritis, Oligoarticular",
author = "Stoll, {Matthew L.} and Li, {Quan Zhen} and Jinchun Zhou and Marilynn Punaro and Olsen, {Nancy J.}",
year = "2011",
month = "7",
language = "English (US)",
volume = "29",
pages = "736--742",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "4",

}

TY - JOUR

T1 - Elevated IgG autoantibody production in oligoarticular juvenile idiopathic arthritis may predict a refractory course

AU - Stoll, Matthew L.

AU - Li, Quan Zhen

AU - Zhou, Jinchun

AU - Punaro, Marilynn

AU - Olsen, Nancy J.

PY - 2011/7

Y1 - 2011/7

N2 - Objective: Although oligoarticular juvenile idiopathic arthritis (oJIA) is considered to carry the best prognosis among the JIA subtypes, many children evolve to a chronic course. A few studies have identified clinical risk factors for disease extension, and recent studies have evaluated synovial fluid markers. However, the only biological marker from the serum studied to date is the anti-nuclear antibody (ANA), regarding which there is mixed data regarding prognosis. No studies have evaluated whether additional autoantibodies may affect the articular prognosis of oJIA. Methods: Microarrays containing candidate autoantigens were printed on slides, which were used to profile 36 children with oJIA and 18 controls. Unsupervised cluster analysis was used to identify distinct subgroups of JIA patients. Response to therapy after a mean interval of 4.9 months was evaluated. Results: Cluster analysis revealed two subgroups of oJIA patients, with identical clustering observed when children with onset over age six were excluded. Cluster 1 had higher levels of multiple autoantibodies compared to both cluster 2 as well as controls, including antibodies against several extracellular matrix (ECM) and nuclear antigens. Although the two patient clusters were similar with respect to clinical features and treatment decisions, children in cluster 1 were less likely to have attained remission by the follow-up visit. Conclusion: Antibodies against ECM and possibly other antigens may identify a sub-group of children with oJIA who will require more aggressive therapy to attain control of the arthritis.

AB - Objective: Although oligoarticular juvenile idiopathic arthritis (oJIA) is considered to carry the best prognosis among the JIA subtypes, many children evolve to a chronic course. A few studies have identified clinical risk factors for disease extension, and recent studies have evaluated synovial fluid markers. However, the only biological marker from the serum studied to date is the anti-nuclear antibody (ANA), regarding which there is mixed data regarding prognosis. No studies have evaluated whether additional autoantibodies may affect the articular prognosis of oJIA. Methods: Microarrays containing candidate autoantigens were printed on slides, which were used to profile 36 children with oJIA and 18 controls. Unsupervised cluster analysis was used to identify distinct subgroups of JIA patients. Response to therapy after a mean interval of 4.9 months was evaluated. Results: Cluster analysis revealed two subgroups of oJIA patients, with identical clustering observed when children with onset over age six were excluded. Cluster 1 had higher levels of multiple autoantibodies compared to both cluster 2 as well as controls, including antibodies against several extracellular matrix (ECM) and nuclear antigens. Although the two patient clusters were similar with respect to clinical features and treatment decisions, children in cluster 1 were less likely to have attained remission by the follow-up visit. Conclusion: Antibodies against ECM and possibly other antigens may identify a sub-group of children with oJIA who will require more aggressive therapy to attain control of the arthritis.

KW - Antibodies

KW - Juvenile idiopathic arthritis

KW - Oligoarticular

UR - http://www.scopus.com/inward/record.url?scp=80055096449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055096449&partnerID=8YFLogxK

M3 - Article

C2 - 21813070

AN - SCOPUS:80055096449

VL - 29

SP - 736

EP - 742

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 4

ER -